INBX 250117 17.50C (INBX250117C17500) Stock Options, News & Quotes

16.70
0.000.00%

15min DelayClose May 28 15:59 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

1 minute ago

🟤 Watchlist, JANUARY 23,2025, Thursday. NFA

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...

Jaguar8

Yesterday 13:03

🟢 Watchlist, JANUARY 22,2025, Wednesday. NFA

Jaguar8

Yesterday 06:02

one complete response (CR), three partial responses (PR), and six cases of stable disease (SD

$Inhibrx Biosciences (INBX.US)$

Jaguar8

Yesterday 06:01

NEWS

$Inhibrx Biosciences (INBX.US)$
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Tuesday, 21st January at 5:01 pm
SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial...